Glossary of Patient Engagement Terms
The definitions of these terms, which includes Family Caregiver, Meaningful Engagement, and Patient-Focused Drug Development, stem largely from our patient engagement work, including our ‘Patient-Focused Drug Development – Recommended Language for Use in Guidance Document Development’ Paper with Genetic Alliance, as well as our Value Rubric, and Representativeness Rubric.
family caregiver: someone caring for those with a medical condition(s). Their care recipients are dependent on the health care system after the diagnosis of a medical condition or disability. A caregiver’s views on health issues, such as the benefit and risk of new treatments, will vary depending on the severity of the condition and personal circumstances of those they care for. 1,2
family caregiving organization: a 501(c)(3) organization that has a mission invested in improving the lives of family caregivers and their care recipients. It engages in programs, such as research, education, advocacy, and service to family caregivers. It takes a holistic view of the caregivers it represents and seeks universal support from stakeholders for its mission and programs. 1,2
meaningful engagement: direct relationships and partnerships that are bidirectional, reciprocal, and continuous. Communications are open, honest, and clear. Engagement goals, participants, methods, desired impacts, and actual impacts are clearly outlined and transparent.1
online patient communities: Internet-based platforms that unite patients who have been diagnosed with a disease. They offer support, networking and/or information sharing.3,4 Platforms may also help patients record health information and/or become involved in research. For researchers, online patient communities can be a useful resource for identifying patients to recruit as advisers or to participate in a study (e.g., qualitative study on patient experience, clinical trial participant, or surveys of opinions/experiences). Online communities are operated by patient organizations, provider groups, and others including for-profit organizations. For-profit organizations should not be confused with patient organizations, as they typically collect data but do not advocate for a specific constituency and utilize patient data primarily for commercial purposes.
patient: someone having or at-risk of having a medical condition(s), whether or not they currently receive medicines or vaccines to prevent or treat a disease. They are dependent on the health care system after the diagnosis of a medical condition or disability. A patient relies on the health care system to feel better and to have a longer, healthier, and more robust life. An individual patient’s views on health issues, such as the benefit and risk of new treatments, will vary depending on the severity of his or her condition and personal circumstances.2
patient advocacy organization: a 501(c)(3) organization that has a mission to combat a particular disease, disability, or group of diseases and disabilities, or to improve and protect the health of a particular group of people. It engages in programs, such as research, education, advocacy, and service to individuals and communities. It takes a holistic view of the conditions for the patients it represents and seeks universal support from stakeholders for its mission and programs. While a patient advocacy organization may advocate for patient access to care, they do not have prescribing authority; formulary control, responsibility, or decision-making authority; or make drug purchases.2
patient centered: Any process, program or decision focused on patients in which patients play an active role as meaningfully engaged participants, and the central focus is on optimizing use of patient-provided information. Patient centered means doing things WITH –not FOR or TO –patients.6
patient-centered core outcome set (PC-COS): An agreed upon, standardized set of outcomes (often with related measures, and/or endpoints identified) that should be gathered from patients and reported at a minimum in research in specific areas of health or health care. They include, but are not limited to how patients feel and function, mortality, biomarkers as surrogate outcomes, etc. The outcome-concept identification and prioritization are guided by patient contributions as partners, recognizing their unique experiences, values, and expertise.5
patient-centered core impact set (PC-CIS): An agreed upon, standardized set of impacts on a patient’s daily life that should be gathered from patients and reported at a minimum in research in specific areas of health or health care. The impact-concept identification and prioritization are guided by patient contributions as partners, recognizing their unique experiences, values, and expertise. The term “impacts” includes health outcomes, such as what would be found in a core outcome set, and any other patient experience information (e.g., financial- or caregiver-related burdens) patients might report as important to them.
patient-centered health care: care that is respectful of and responsive to individual patient preferences, needs, and values in context of their own social worlds. Patient centeredness is created by engaging, informing, and actively listening to people with chronic conditions at every point of contact –from the research bench to the bedside and everywhere in between.1,7,8
patient-centered outcome (PCO): The outcomes reported by patients as important to them in the way they experience a disease or treatment for that disease.6
patient-centered value assessment (VA): Patients are engaged, heard, understood, and respected throughout the entire VA process, and their input is incorporated and guides decision-making.
patient community: broadly encompasses individual patients, family caregivers, and the organizations that represent them. The patient community is heterogeneous and brings to the value discussion different perspectives that have been informed by their experiences, trajectory or stage of disease, level of expertise, and many other factors.1
patient engagement in research: Refers to “the active, meaningful, authentic and collaborative interaction between patients and researchers across all stages of the research process, where research decision-making is guided by patients’ contributions as partners, recognizing their unique experiences, values and expertise.”14 This definition is also applicable across stakeholders and engagement activities (e.g., participation in an interview, focus group).
patient-focused drug development: the meaningful engagement of patients in the research and development of therapeutic products and the various important roles patients can play in improving the processes, from study endpoint selection that reflects outcomes meaningful to patients, recruitment and retention in clinical trials, and more effective post-marketing safety surveillance.9,10
patient information: broadly means all information regarding a patient from any source, such as patient-provided information as well as other medical information about a patient, including but not limited to: test results (e.g., genetic, pathology, imaging), identifying information, family history, provider opinion, and any other information in a patient’s medical records.1,15
patient perspective information: a subset of patient-provided information; information regarding the attitude or the point of view of the patient, including anecdotal comments in correspondence to FDA or testimony at Advisory Committee Panel meetings 17 or Patient-Focused Drug Development meetings18 patient opinions expressed publicly including through social media, patient responses to qualitative, ad hoc surveys, quantitative measurements of patient-reported outcomes, and more.1,16,19
patient preference information: a subset of PPIn; qualitative or quantitative assessments of the relative desirability, or acceptability of, attributes that differ among alternatives (e.g., alternative therapeutic strategies).19Attributes of a drug or biologic include characteristics such as effectiveness, safety, route of administration, dosing regimens, duration of effect, duration of use, and other product features about which patients express preferences.1
patient-provided information (PPIn): describes information a patient contributes directly at any point during the product lifecycle. The term broadly encompasses the entirety of information that can be collected from an interaction with a patient. The focus should be the patients view on their disease(s)/condition(s), desired attributes for treatments, experiences with treatments, benefit- risk preferences, and desired goals and outcomes. It should not be primarily focused on any one product.1,2
patient-reported outcome (PRO): a subset of PPIn; an outcome measure based on a report that comes directly from the patient (e.g., study subject) about the status of the patient’s health condition without amendment or interpretation of the patient’s response by a clinician or anyone else. A PRO can be measured by self-report or by interview provided that the interviewer records only the patient’s responses.1,6,13
patient risk tolerance: a qualitative term reflecting the extent to which a patient will accept the risk(s) of an adverse effect from a treatment for a probable benefit; risk tolerance will vary among patients, which affects individual patient decisions as to whether risks are acceptable.1,20
representativeness: a sufficient number of and types of people are included in the engagement activity to ensure that those engaged can speak on behalf of the target population. It refers to “who” and “how many” individuals to include in an interaction in order to, as closely as possible, engage with individuals that represent the broader, target patient population.21
How to cite this report:
National Health Council Patient Engagement Glossary of Terms. Washington DC: National Health Council; 2019. Available from: https://nationalhealthcouncil.org/glossary-of-patient-engagement-terms/
1See National Health Council. The Patient Voice in Value: The National Health Council Patient-Centered Value Model Rubric, https://www.nationalhealthcouncil.org/wp-content/uploads/2019/12/Value-Rubric.pdf.
2National Health Council, Genetic Alliance. Dialogue/Advancing Meaningful Patient Engagement in Research Development, and Review of Drugs. (https://www.nationalhealthcouncil.org/wp-content/uploads/2019/12/PatientEngagement-WhitePaper.pdf)
3van der Eijk M, Faber MJ, Aarts JW, Kremer JA, Munneke M, Bloem BR. Using Online Health Communities to Deliver Patient-Centered Care to People With Chronic Conditions. J Med Internet Res. 2013;15(6). doi:10.2196/jmir.2476
5Adapted from: COMET Initiative. Core Outcome Measures in Effectiveness Trials. Available from: http://www.comet-initiative.org/
6National Health Council. The National Health Council Rubric to Capture the Patient Voice: A Guide to Incorporating the Patient Voice into the Health Ecosystem. June 2019. Washington, DC. Available from: https://www.nationalhealthcouncil.org/Patient-Engagement-Rubric
9See Clinical Trials Transformation Initiative, CTTI Recommendations: Effective Engagement with Patient Groups Around Clinical Trials, http://www.ctti-clinicaltrials.org/files/PatientGroups/PGCTrecs.pdf (last visited February 16, 2016).
10National Health Council, Genetic Alliance. Patient-Focused Drug Development – Recommended Language for Use in Guidance Document Development , (https://www.nationalhealthcouncil.org/wp-content/uploads/2019/12/NHC-GA%20Feb201…
11See patient-generated health data, HealthIT.gov website, Consumer eHealth, https://www.healthit.gov/topic/scientific-initiatives/patient-generated-health-data (last visited April 8, 2016).
12The Voice of the Patient: A Series of Reports from FDA’s Patient-Focused Drug Development Initiative, http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm368342.htm (last visited February 16, 2016)
13See the guidance for industry, Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims (http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/…).
14ISPOR Patient-Centered SIG. Defining Patient Centeredness and Engagement in HEOR: Proposed Definition and Stakeholder Response. https://www.ispor.org/docs/defaultsource/presentations/1388.pdf?sfvrsn=c…Published May 21, 2018. Accessed April 15, 2019.
15National Health Council, Genetic Alliance. Integrating the Patient into the Drug Development Process: Developing FDA Guidance, (https://www.nationalhealthcouncil.org/sites/default/files/NHC-GA-Patient-Engagement.pdf).
16See FasterCures, Enhancing Integration of Patient Perspective Data in the Drug Development Process, Proposal for PDUFA VI, (https://www.nationalhealthcouncil.org/sites/default/files/FasterCures-PDUFA-Comment-Letter-FDA.pdf).
17See FDA website, About the Patient Representative Program, (https://www.fda.gov/patients/learn-about-fda-patient-engagement/about-fda-patient-representative-program) (last visited February 16, 2016).
18See Patient-Focused Drug Development: Disease Area Meetings Planned for Fiscal Years 2013-2017, http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm347317.htm (last visited February 16, 2016).
19Draft Guidance for Industry, Food and Drug Administration Staff; and Other Stakeholders; Patient Preference Information – Submission, Review in PMAs, HDE Applications, and De Novo Requests, and Inclusion in Device Labeling. For the most recent version of a guidance, check the FDA Drug guidance Web page at https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs (last visited February 16, 2016).
20See CDRH guidance for industry, Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions, http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm506679.pdf (last visited November 7, 2016).
21National Health Council. Tackling Representativeness: A Roadmap and Rubric. Washington, DC. Available from: (https://www.nationalhealthcouncil.org/sites/default/files/Representativeness%20in%20Patient%20Engagement.pdf)